InsiderStreet Equity Research

Produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation for any investor. Do not rely on it for any investment decision.

Last Close

$69.57

2026-10-16

Market Cap

$31.4B

Volume

3.1M

52-Wk High

$89.77

52-Wk Low

$58.75

Trailing PE

20.0

P/S

1.55

Gross Margin

42.9%

Net Margin

7.9%

ROE

15%

ROIC

8%

Piotroski

5/9

Altman Z

1.7

1-Yr Return

-5.2%

5-Yr Return

+16.5%

GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals â molecular tracers labeled with radioisotopes â injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.

SectorHealthcareIndustryMedical - DevicesExchangeNASDAQMarket Cap$31.4BEmployees54,000 (SEC-filed)CEOPeter J. ArduiniIPO2022-12-15CountryUS

500 West Monroe Street, Chicago, IL 60661 · Tel 833 735 1139 · gehealthcare.com

INSIDERSTREET SCORE26 / 100Street mean $85.25 (4 analysts, last qtr) — their number, not ours

INSIDER CONSENSUS SIGNALNET BUYING$6.4M open-market purchases vs $0.0M sales / 6 mo

1 Year vs S&P 500 · GEHC -5.2% · S&P 500 +15.9% · spread -21.0pp

4 Years vs S&P 500 · GEHC +16.5% · S&P 500 +108.9% · spread -92.5pp

Both charts indexed to 100 at the start of their window and drawn on a single shared scale, so the gap to the benchmark is the gap you see. Adjusted closes throughout.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

INSIDERSTREET
SCORE26of 100

Score Breakdown

Profitability	46/100
Growth	23/100
Momentum	44/100
Quality	61/100
Earnings Quality	70/100
Balance Sheet	48/100
Value	57/100
Risk (safety)	30/100
Overall	26.1/100

Each component is a diagnostic reading on its own 0-100 scale. The overall score is computed separately from the underlying financials and is not the average of the rows above — components are not equally weighted and three of them (Momentum, Value, Risk) are derived partly from price rather than from the business.

Peer Comparison — IS Score

Symbol	IS Score
DXCM	81
EW	65
ZBH	60
BSX	67
PEN	68
SNN	76
GEHC	26

IS Score Trend — quarterly

14 quarters, 23 Q1 to 26 Q2. Peak 65 in 24 Q1, latest 26 — -39 since. Fell in 4 of the last 4 quarters. Dashed line marks 40 on the 0-100 scale.

BUSINESS QUALITY26 / 100IS Score 26.1 / 100 · -38.6 from peak of 65

Fundamental factor model, quarterly. Measures how the business is doing - not where the price is going.

PRICE STRUCTUREBULLISHTechnical Score 76 / 100 · Power +52 · 17 of 22 indicator votes bullish

Vote share across trend, momentum, volume, volatility and pattern families. Describes where the price is, not where it is going.

These two disagree — business quality 26, price structure 76 out of 100, so the price reads better than the business does. We publish the disagreement rather than resolving it: they answer different questions, and the gap between them is information, not an error.

Trigger	Where it stands now	What it would mean
IS Score reaches 55 and holds two consecutive quarters	now 26.1	would move us up one band
IS Score stops falling - one quarter higher than the prior	last four: 51 → 45 → 34 → 26	the direction matters more than the level
Technical vote share back above 50%	now 82%	price structure no longer broken
Institutional holder count rises two quarters running	peak 1,357 → now 1,230	fewer institutions willing to hold is our clearest warning

We publish these so the view can be shown to be wrong. If none of them move and our reading does, we owe you an explanation.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

This page is InsiderStreet's own reading, produced from the data in the rest of this document. It is not a price target and not investment advice. Analyst consensus and street price targets appear later under their own heading and are the street's numbers, not ours.

Site Convergence Score4 of 4top 0% of 29,420 symbols

Sources Aligned— of 3independent disclosures

Congress (180d)6 buys2026-09-11

Insider Buys (180d)8$6.42M

ETF Funds (30d)1128 up / 944 downnet +184 funds

Institutions Added (13F)-37managers opening or increasing

Congressional and insider figures are disclosed purchases in the trailing 180 days; ETF figures are COUNTS OF FUNDS whose holding changed in 30 days, not dollars. Coincidence of separate disclosures, not coordination. An absent source means nothing qualifying was disclosed in its window.

Institutions holding — 12 quarters

Peak 1,357 · latest 1,230 (-127 from peak).

Quarter	Holders	13F shares	Value	Reported own%
2026 Q2	1,230	397.3M	$25.1B	87.7%
2026 Q1	1,267	390.7M	$27.3B	86.2%
2025 Q4	1,326	407.5M	$32.5B	90.0%
2025 Q3	1,269	378.1M	$27.7B	83.5%
2025 Q2	1,303	381.5M	$27.6B	84.2%
2025 Q1	1,357	382.2M	$30.0B	84.4%
2024 Q4	1,317	387.8M	$29.1B	85.6%
2024 Q3	1,257	379.7M	$34.4B	83.8%
2024 Q2	1,202	373.0M	$27.8B	82.3%
2024 Q1	1,247	370.7M	$32.0B	81.8%
2023 Q4	1,172	371.9M	$27.2B	82.1%
2023 Q3	1,089	368.3M	$23.8B	81.3%

How to read ownership above 100%. A 13F reports the positions a manager has investment discretion over, and where two or more managers share discretion over the same block, each one reports it. Summed across filers, the total can therefore exceed the shares actually outstanding without anything being wrong. We publish the figure as filed rather than netting it down, and flag separately any quarter where the arithmetic is not merely high but impossible.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Insider	Role	Date	Type	Shares	Value	Post-Txn Owned
Grogan William K	Chief Financial Officer	2026-09-14	A-Award	62,256	—	62,256
Grogan William K	Chief Financial Officer	2026-09-14	A-Award	12,840	—	75,096
Grogan William K	Chief Financial Officer	2026-09-14	A-Award	31,877	$2.05M	31,877
Rackliffe Philip	CEO, AIS	2026-09-03	TAX W/H	798	$0.06M	41,533
O'Neill Kevin Michael	CEO, PDx	2026-09-03	TAX W/H	718	$0.05M	32,026
Newcomb George A.	Chief Accounting Officer	2026-09-03	TAX W/H	112	$0.01M	10,515
Kass-Hout Taha	Chief Technology Officer	2026-09-03	TAX W/H	1,502	$0.11M	88,467
Jimenez Frank R	GC & Corporate Secretary	2026-09-03	TAX W/H	1,480	$0.10M	89,321

6-mo decomposition (Form 4)	Txns	Shares	Value	Signal weight
P — Open-market purchases	8	103,652	$6.4M	Counted
F — Tax withholding	21	39,154	$2.7M	None — compensation

Monthly Net Insider Flow (000 shares)

Net of acquisitions minus dispositions, all Form 4 types.

Signal Summary

SignalNet Buying

Open-Market Sells$0.0M0 txns / 6 mo

Open-Market Buys$6.4M8 txns / 6 mo

ClusterNone active3+ insiders / 21 days

Filed	Filer	Shares registered	Est. proceeds
2025-11-24	Kenneth Stacherski	4,585	$0.4M
2025-10-27	Kenneth Stacherski	4,585	$0.4M
2025-09-22	Kenneth Stacherski	19,524	$1.5M
2025-09-12	Kenneth Stacherski	11,757	$0.9M
Trailing 12 mo	4 filings	40,451	$3M

Filed	Form	Reporting person	% of class	Shares
2026-08-07	SCHEDULE 13G/A	Dodge & Cox	8.30%	37.9M sh
2026-08-07	SCHEDULE 13G/A	Dodge & Cox	10.50%	47.3M sh
2026-05-14	SCHEDULE 13G/A	Capital Research Global Investors	4.60%	21.1M sh
2026-04-29	SCHEDULE 13G	Vanguard Capital Management	7.31%	33.4M sh

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Member	Chamber	Trade	Size band	Traded	Disclosed
Ro Khanna	House	BUY	$1,001 - $15,000	2026-09-11	2026-10-09
Ro Khanna	House	BUY	$1,001 - $15,000	2026-07-30	2026-08-12
Ro Khanna	House	BUY	$1,001 - $15,000	2026-07-07	2026-08-12

House 12-Mo15 trades7 purchases

Senate 12-Mo0 tradesNone purchases

CoverageSTOCK Act filings30-45 day disclosure lag

13F Filers (last complete Q)1,267

13F Shares391M86.2% of shares out

New / Closed129 / 159positions, QoQ

Increased / Reduced389 / 481positions, QoQ

Put/Call (13F)0.88option positions

Free Float99.7%450M sh

2.8 · Largest Reporting 13F Managers

Manager	Shares	Value
Perpetual Ltd	2.7M	$177M
Td Waterhouse Canada Inc.	608,890	$39M
Wedge Capital Management L L P/Nc	379,660	$25M
Auto-Owners Insurance Co	353,051	$23M
Jia Investment Alliance Pte. Ltd.	310,700	$20M
Douglas Lane & Associates, Llc	276,439	$18M

EDGAR 13F holdings as of 2026-09-30; filer values normalized to dollars.

2.9 · Top ETF & Fund Ownership

Fund	Weight	Position
VITSX	0.0%	$937M
VTSAX	0.0%	$937M
VTI	0.0%	$937M
VSMPX	0.0%	$937M
VFINX	0.0%	$775M
VFFSX	0.0%	$775M

13F Filers Holding GEHC — quarterly

Institutional Put/Call — quarterly

Daily short-sale volume as % of volume reported in FINRA's short-sale file — a flow measure, not short interest; dashed = 50-day average.

Latest Session56.3%2026-10-15

20-Day Avg62.0%50-day 60.5%

TrendRising20d vs 50d

By Market CenterQ: 55% · N: 85% · B: 6%latest session

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Weekly Notional ($B)

Where GEHC Trades in the Dark

ATS Venue (4-wk)	Shares	Avg trade
Incr Intelligent Cross Llc	3.6M	52 sh
Ubsa Ubs Ats	3.5M	62 sh
Sgmt Sigma X2	2.2M	53 sh
Mstx Ms Trajectory Cross (Ats-1)	2.1M	50 sh
Ebxl Level Ats	2.0M	31 sh
Pure Purestream	1.3M	23 sh

Where a dollar of GE HealthCare Technologies Inc. revenue goes. All values FY2025 filings, live.

Region	Revenue	Share
Other Countries	$9.4B	46%
UNITED STATES	$9.2B	44%
CHINA	$2.0B	10%

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

GEHC (live moat model)Peer median: DXCM · EW · ZBH · BSX · PEN

Component scores from the live moat model. Peer median illustrative.

Moat score 48/100 — Weak; primary source Cost Advantage.

3.8 · Employees (SEC filings)

Officer	Title
Peter J. Arduini	President, Chief Executive Officer & Director
Frank R. Jimenez	General Counsel & Corporate Secretary
Taha Kass-Hout	Chief Science & Technology Officer
Adam Holton	Chief People Officer

Revenue ($B)

EPS ($) — GAAP diluted actual, street-basis estimate

Actual bars are GAAP diluted EPS from the filed income statement; the lighter forward bars are street-basis consensus. The two are different measures and are not comparable quarter to quarter.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Quarterly EPS — Actual vs. Consensus

Beats (>2%)4 of 6recent quarters

Avg Surprise+5.8%

Next Report2026-10-28

Income Quality0.70OCF ÷ net income

Beat Rate—%0 of 0 quarters

Current Streak0longest 0

Avg EPS Surprise—%median —%

Surprise Trend—last 4 vs prior 4

Period	EPS est.	EPS actual	EPS surprise	Rev est. ($M)	Rev actual ($M)	Rev surprise

Announcement dates to . Consensus as it stood at each report. Revenue surprise shown where both estimate and actual are filed. A beat record is history, not a forecast.

Profit Margins (%)

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Revenue by Segment — Stacked

Live segmentation data.

YoY Growth Heatmap — Income Lines

YoY growth	FY21	FY22	FY23	FY24	FY25
Revenue	+2.5%	+4.3%	+6.6%	+0.6%	+4.8%
Gross profit	+6.0%	+0.1%	+10.3%	+3.6%	+0.5%
Operating income	+2.8%	-9.8%	-3.4%	+7.8%	+5.2%
Net income	-83.8%	-14.7%	-18.2%	+27.1%	+4.6%

$B · FY ends	FY21	FY22	FY23	FY24	FY25
Revenue	17.6	18.3	19.6	19.7	20.6
Cost of revenue	10.4	11.2	11.6	11.5	12.4
Gross profit	7.2	7.2	7.9	8.2	8.2
R&D expense	0.8	1.0	1.2	1.3	1.3
SG&A expense	3.6	3.6	4.3	4.3	4.2
Operating income	2.8	2.5	2.4	2.6	2.8
EBITDA	3.5	3.2	3.5	3.7	3.8
D&A	0.6	0.6	0.6	0.6	0.6
Pretax income	2.9	2.5	2.4	2.6	2.8
Income tax	0.6	0.6	0.7	0.5	0.6
Net income	2.2	1.9	1.6	2.0	2.1
Diluted EPS ($)	4.90	4.22	3.02	4.34	4.55
Diluted shares (M)	455	454	458	459	460

Operating CF$2B

CapEx$0B

Free cash flow$2B

SBC$0B

Buybacks$0B

Net cash change$2B

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet — Full

$B	FY22	FY23	FY24	FY25
Cash & equivalents	1.4	2.5	2.9	4.5
ST investments	0.0	0.0	0.0	0.0
Receivables (net)	4.0	4.3	4.4	4.0
Total current assets	7.8	9.0	9.5	10.7
PP&E (net)	2.3	2.5	2.6	3.1
Goodwill + intangibles	14.3	14.2	14.2	14.6
Total assets	27.5	32.5	33.1	36.9
Accounts payable	3.1	2.9	3.0	3.2
Short-term debt	0.1	1.1	1.5	0.5
Deferred revenue	1.9	1.9	1.9	0.0
Total current liabilities	7.2	9.0	9.6	9.1
Long-term debt	8.2	8.4	7.4	9.5
Total liabilities	17.9	25.1	24.4	26.3
Shareholders' equity	9.6	7.3	8.7	10.6

Cash Flow Statement — Full

$B	FY22	FY23	FY24	FY25
Net income	1.9	1.6	2.1	2.2
D&A	0.6	0.6	0.6	0.6
Stock-based compensation	0.1	0.1	0.1	0.1
Working capital change	(0.3)	0.0	(0.1)	(0.4)
Operating cash flow	2.1	2.1	2.0	2.0
Capital expenditures	(0.3)	(0.4)	(0.4)	(0.5)
Investing cash flow	(0.4)	(0.6)	(0.9)	(1.0)
Buybacks	0.0	0.0	0.0	(0.2)
Dividends paid	0.0	(0.0)	(0.1)	(0.1)
Debt issuance / (repay)	8.2	1.1	(0.4)	1.0
Financing cash flow	(0.8)	(0.5)	(0.6)	0.6
Free cash flow	1.8	1.7	1.6	1.5

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet Structure ($B)

Cash Generation vs Capex ($B)

Left: what the balance sheet is made of — the gap between the assets bar and the liabilities bar is book equity. Right: whether the capex bar is covered by the operating-cash bar; where it is not, the difference was funded externally and free cash flow goes negative.

Ratio	FY22	FY23	FY24	FY25	TTM
PROFITABILITY
ROE	5.9%	19.0%	25.6%	17.8%	15%
ROA	2.0%	5.2%	6.1%	4.8%	4.3%
ROIC	3.7%	11.5%	14.0%	13.0%	8.1%
Gross margin	39.1%	40.5%	41.7%	40.0%	42.9%
Operating margin	13.8%	12.5%	13.3%	13.4%	12.7%
Net margin	10.4%	8.0%	10.1%	10.1%	7.9%
EBITDA margin	17.3%	18.0%	18.6%	18.4%	15.2%
FCF margin	19.5%	8.8%	7.9%	7.7%	—
VALUATION
P/E	47.62	22.51	17.97	22.46	20.0
P/B	2.82	4.95	4.24	3.64	2.9
P/S	5.34	1.81	1.82	1.93	1.55
P/FCF	27.34	20.60	23.11	25.06	35.1
EV/EBITDA	35.79	12.14	11.52	12.08	12.8
EV/Revenue	6.80	2.18	2.15	2.21	1.9
Earnings yield	2.1%	4.4%	5.6%	4.5%	5.05%
FCF yield	3.7%	4.9%	4.3%	4.0%	2.85%

Ratio	FY22	FY23	FY24	FY25	TTM
LEVERAGE & SOLVENCY
Current ratio	1.09	1.00	1.00	1.18	1.02
Quick ratio	0.79	0.78	0.79	0.93	0.72
Debt / equity	0.92	1.38	1.11	0.96	0.92
Debt / assets	31.4%	30.4%	28.3%	27.1%	27.1%
Net debt / EBITDA	7.67	2.09	1.77	1.53	2.60
Interest coverage	12.97	5.36	6.06	5.78	—

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Ratio	FY22	FY23	FY24	FY25	TTM
EFFICIENCY
Asset turnover	0.18	0.65	0.60	0.56	0.54
Receivables turnover	1.27	4.89	4.75	4.83	5.2
DSO (days)	287	75	77	75	70
DPO (days)	375	95	95	103	102
Cash conversion cycle	173	45	44	41	46
GROWTH (YoY)
Revenue growth	—	295.9%	0.6%	-0.4%	—
Net income growth	—	183.0%	27.1%	-15.7%	—
EPS growth	—	180.5%	26.8%	-15.9%	—
FCF growth	—	77.6%	-9.6%	-2.8%	—
PER SHARE ($)
EPS (diluted, TTM)	1.22	3.42	4.34	3.65	3.51
Book value / share	20.61	15.57	18.40	22.55	24.26
Revenue / share	10.88	42.69	42.86	42.58	44.69
FCF / share	2.13	3.74	3.38	3.27	1.98
Cash / share	3.18	5.47	6.30	9.80	4.65
SHAREHOLDER RETURN & SCORES
Buyback yield	0.0%	0.0%	0.0%	0.3%	1.38%
Altman Z-Score	1.18	1.80	1.92	1.88	1.7
Piotroski F-Score	4	7	5	6	5/9
Beneish M-Score	—	-2.50	-2.47	-2.69	-2.53

Model	Score	Zone	Note
Piotroski F-Score	5 / 9	Middling
Altman Z-Score	1.7	Distress (<1.81)	Distress
Income quality	0.70	Accrual-heavy	OCF ÷ net income
Beneish M-Score	-2.53	Non-manipulator	vs −2.22 threshold

DuPont Decomposition (TTM)	Value
Tax burden	0.78
Interest burden	0.83
Operating margin	12.2%
Asset turnover	0.56×
Financial leverage	3.52×
= ROE	15%

Growth Quality (live)	Value
Revenue stability	0.70
Earnings stability	0.22
Earnings persistence	0.88
Revenue CAGR 3y	11.9%
EPS CAGR 3y	6.1%
FCF CAGR 3y	-8.1%

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Buyback Yield1.38%

Dividend Yield0.20%

Total Shareholder Return1.56%cash yield

SBC / Revenue0.6%dilution pressure

Company	Mkt cap	P/E	ROE	Net margin	Rev growth	Piotroski	1-yr ret
DXCM	$32.5B	33.2	38%	19.0%	+15.5%	9/9	+29.7%
EW	$49.9B	49.8	9%	13.9%	+14.6%	6/9	+19.2%
ZBH	$18.1B	23.0	6%	9.1%	+8.6%	6/9	-5.0%
BSX	$64.3B	17.9	15%	16.7%	+13.5%	8/9	-54.6%
PEN	$12.6B	78.4	11%	8.9%	+17.6%	6/9	—
SNN	$12.2B	19.0	22%	9.8%	+11.5%	8/9	—
ALGN	$10.5B	25.6	10%	10.3%	+4.4%	7/9	—
GMED	$10.3B	19.3	12%	19.2%	+19.7%	8/9	—

1-yr returns computed from adjusted price history; peers without a tracked series show —.

Buy

19 Analysts

Str Sell (0)Sell (0)Hold (8)Buy (11)Str Buy (0)

Mean Target (qtr)$85.254 targets

Target vs. Price+22.5%last-quarter mean

Next Report2026-10-28street $1.21

Consensus estimates	Revenue mean	High / Low	EPS mean	High / Low	# EPS est.
FY2026	$21.72B	$21.83B / $21.56B	$4.92	$4.99 / $4.89	13
FY2027	$22.73B	$22.86B / $22.47B	$5.43	$5.58 / $5.15	13
FY2028	$23.81B	$24.43B / $23.33B	$6.04	$6.40 / $5.40	9

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Street Price Target — Trajectory

Window	Avg Target	vs. Price	# Targets
Last Month	$89.00	+27.9%	2
Last Quarter	$85.25	+22.5%	4
Last Year	$84.72	+21.8%	29
All Time	$87.30	+25.5%	47

Rolling mean of published targets vs. last close $69.57. Aggregated from StreetInsider, Benzinga.

Third-Party Composite Rating

B+

DCF

4/5

ROE

4/5

ROA

4/5

Debt/Eq

1/5

P/E

3/5

P/B

3/5

Independent quant composite as of 2026-10-16; components scored 1–5 (5 best). Shown for contrast with the InsiderStreet Score — methodologies differ.

GEHC -5.2% vs S&P 500 +15.9% — spread -21.0pp

Sector — XLV +24.2%

Peer Set — indexed to 100

All series indexed to 100 at the start of the window, adjusted closes.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Candlesticks with SMA 20/50 overlay, Bollinger (20,2σ) band, volume, and Wilder RSI(14) — computed from live daily OHLCV.

Moving Average	Value	Distance	% Distance	Signal
SMA 20	$66.36	+3.21	+4.84%	Above
SMA 50	$68.59	+0.98	+1.43%	Above
SMA 200	$70.47	-0.90	-1.28%	Below
EMA 9	$67.87	+1.70	+2.50%	Above
EMA 21	$67.02	+2.55	+3.80%	Above
EMA 50	$67.18	+2.39	+3.56%	Above
EMA 200	$69.56	+0.01	+0.01%	Above

Series and readings from the nightly technical-indicator history — identical data to the site's ribbon chart. Supertrend segments colored by direction.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

TECHNICAL VERDICTBULLISHPower Score +5217 of 22 indicator votes bullish

Family Scores (site weights)

Trend 30%78

Momentum 25%82

Volume 20%81

Volatility 10%100

Patterns 15%38

This Week82% bullishof 11 price-based votes

4 Weeks Ago0%+82 pts since

12 Weeks Ago0%+82 pts since

ReadImprovingweek-over-week trajectory

Price vs SMA 20$66.36

Price vs SMA 50$68.59

Price vs SMA 200$70.47

EMA 9/21 Cross67.9/67.0

SMA 50/200Death

ADX DirectionADX 22

Supertrend$65

Parabolic SAR$65

SMA Slope0.270

RSI61.0

Stochastic K/D84/87

StochRSI K/D93/96

Williams %R-22

CCI184

TSI vs Signal7.2

CMO22.0

ROC8.21%

OBV SignalDistrib

Chaikin MF0.110

MFI53

Force Index1M

Elder Ray Bull4.27

RSI (14)30 oversold · 70 overbought

Stochastic %Kvs %D 87

Money Flowvolume-weighted RSI

ADXtrend strength · <20 weak

Williams %Rinverted scale

Level	Value	Level	Value
Pivot / R1 / R2	$70.28 / $71.06 / $71.77	S1 / S2	$69.57 / $68.79
Bollinger (20,2)	$62.81 – $69.90	Squeeze	Off
52-wk range	$58.75 – $89.73	Off 52-wk high	-22.5%
ATR (14)	$1.73 (2.5%)	Historical vol	24.4%

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

+7.1%Jan50%

+9.1%Feb75%

-2.8%Mar25%

-9.0%Apr0%

+0.8%May33%

+2.8%Jun100%

+0.6%Jul33%

-0.7%Aug67%

+4.6%Sep67%

-2.4%Oct0%

+1.1%Nov67%

+1.6%Dec50%

Sample: 4 years — treat short histories as suggestive, not statistical.

Computed from live weekly prices	GEHC	S&P 500
Weekly volatility (σ, 1y)	4.97%	1.83%
Best / worst week (1y)	+17.1% / -11.3%	—
Max drawdown (5y, monthly)	-33.0%	—
1-week VaR (95%)	-8.9%	—
Beta (5y)	0.82	1.00

GEHC EQUITY WEATHER (LIVE)PARTLY CLOUDY · +17

Trend+24

Momentum+54

Volume+41

Volatility-60

Breadth-30

MARKET REGIME (2026-10-16)NEUTRAL

VIX19.99Normal

Dow TheoryConfirmed Bearish

SPY / QQQ TSI7.2 / 4.7trend strength

Sector Strength46/100breadth average

Average sentiment of 235 stories, weekly buckets, −1 to +1.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Overall+16.8+37.0 vs industry

Trend+23.6+45.7 vs industry

Momentum+54.1+76.1 vs industry

Volume+41.2+46.2 vs industry

Reading	GEHC	Medical - Devices n=524	Healthcare n=5,272	All US symbols n=70,435
Overall	+16.8	-20.2	-24.0	-20.5
Trend	+23.6	-22.1	-25.6	-21.3
Momentum	+54.1	-22.0	-28.5	-15.8
Volume	+41.2	-5.0	-25.0	-3.8

Trend, momentum and volume are computed per company. Volatility and breadth are market-regime values shared by every symbol in the universe, so they are reported once under Market Regime rather than compared here - a company cannot differ from its sector on a constant.

Pillar (live disclosure scores)	Score
Environmental	62
Social	73
Governance	70
Composite ESG	68

Composite ESG Trend

Filed	8-K contents	Items
2026-09-22	Officer/Director Change; Regulation FD; Exhibits	5.02,7.01,9.01
2026-08-18	Officer/Director Change; Exhibits	5.02,9.01
2026-07-29	Regulation FD; Exhibits	7.01,9.01
2026-07-29	Earnings Release; Exhibits	2.02,9.01
2026-07-23	Earnings Release; Officer/Director Change; Exhibits	2.02,5.02,9.01
2026-04-29	Earnings Release; Exhibits	2.02,9.01
2026-03-17	Departure/Election of Directors; Appointment of Officers; Regulation F	5.02,7.01,9.01
2026-02-27	Entry into Material Definitive Agreement; Termination of Material Defi	1.01,1.02,2.03,9.01

Methodology. Every figure originates in InsiderStreet's production data layer and is computed deterministically by the same engines that power insiderstreet.ai. This factsheet contains no model-written text. Sections without underlying data are omitted rather than estimated.

DISCLOSURES. This document is produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation tailored to any person. Data is sourced as of the dates shown and may no longer be current. InsiderStreet.ai is not a registered investment adviser or broker-dealer. Investing involves risk, including loss of principal. Past performance does not guarantee future results. Do not make any investment decision based on this document. © 2026 InsiderStreet.ai — all rights reserved. Redistribution prohibited.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Data domain	Source	Coverage for this report
Price & volume	market_db.historical_prices	52 rows
Fundamentals	income_statements_annual	6 rows · 2020 to 2025
Reported vs consensus	fact/earnings_calendar	14 rows · 2023-04-25 to 2026-07-29
Analyst estimates	dim/forward_estimates	3 rows · 2026-12-31 to 2028-12-31
Institutional ownership (13F)	holdings_db.institutional_ownership_summary	18 rows · 2010 to 2026
Insider transactions (Form 4)	edgar/form4	12 rows · 2026-09-01 to 2026-09-14
Proposed sales (Form 144)	edgar/form144	1 record
Beneficial ownership (13D/G)	edgar/13dg	4 rows · 2026-04-29 to 2026-08-07
Short-sale volume (FINRA)	edgar/short_volume_daily	60 rows · 2026-07-23 to 2026-10-15
Dark pool (ATS, tier 1)	edgar/darkpool_weekly	12 rows · 2026-06-15 to 2026-08-31
ETF & fund holding	etf_holdings_changelog (30d)	1 record
Peer set	stock_peers_dynamic	8 rows
Industry medians	industry_medians	1 record
Congressional trades	congress_db (House + Senate)	1 record
ESG	fact/esg_disclosures	1 record

Method. Every figure in this factsheet is looked up from a named field computed in code. It contains no model-written text.

Not covered. Short interest as a percent of float and days-to-cover are not in this data set — the short-sale figures above are FINRA volume, a flow, and cannot support squeeze or covering analysis. Options positioning and intraday data are also absent. 13F ownership is filed 45 days after quarter end and congressional trades are disclosed on a lag, so both describe a past position, not a current one.

GE HealthCare Technologies Inc. (GEHC)

GE HealthCare Technologies Inc. (GEHC)

Score Breakdown

Peer Comparison — IS Score

IS Score Trend — quarterly

GE HealthCare Technologies Inc. (GEHC)

Institutions holding — 12 quarters

GE HealthCare Technologies Inc. (GEHC)

Monthly Net Insider Flow (000 shares)

Signal Summary

GE HealthCare Technologies Inc. (GEHC)

2.8 · Largest Reporting 13F Managers

2.9 · Top ETF & Fund Ownership

13F Filers Holding GEHC — quarterly

Institutional Put/Call — quarterly

GE HealthCare Technologies Inc. (GEHC)

Where GEHC Trades in the Dark

GE HealthCare Technologies Inc. (GEHC)

3.8 · Employees (SEC filings)

GE HealthCare Technologies Inc. (GEHC)

GE HealthCare Technologies Inc. (GEHC)

GE HealthCare Technologies Inc. (GEHC)

Balance Sheet — Full

Cash Flow Statement — Full

GE HealthCare Technologies Inc. (GEHC)

GE HealthCare Technologies Inc. (GEHC)

GE HealthCare Technologies Inc. (GEHC)

GE HealthCare Technologies Inc. (GEHC)

Street Price Target — Trajectory

Third-Party Composite Rating

GE HealthCare Technologies Inc. (GEHC)

GE HealthCare Technologies Inc. (GEHC)

Family Scores (site weights)

GE HealthCare Technologies Inc. (GEHC)

GE HealthCare Technologies Inc. (GEHC)

GE HealthCare Technologies Inc. (GEHC)